A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer

: A PHASE Ib DOSE ESCALATION STUDY ON THE SAFETY, TOLERABILITY AND ACTIVITY OF LIPOSOMAL CURCUMIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER

This is a single center in patient/outpatient, uncontrolled dose escalating study in cancer patients to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of body surface area adjusted doses of liposomal curcumin administered intravenously as an 8 hour infusion once weekly for 8 weeks.

Study Overview

• Status: Completed
• Conditions: Patients w/Advanced Cancer That Failed Std of Care Therapy
• Intervention / Treatment: Drug: Liposomeal curcumin

Detailed Description

Patients with solid tumors who either failed to initially respond to approved chemotherapy or who have progressive solid tumor cancers following initial response to approved chemotherapy, are eligible for treatment in this phase 1b trial of ascending doses of intravenous liposomal curcumin following a four week period without previous chemotherapy.The escalating dose range of liposomal curcumin will be from 100mg/M2 to 300 mg/M2 in cohorts of three to 6 patients, and administered over eight hours by a syringe pump weekly for eight weeks. Safety and tolerability will be determined by drug related adverse symptoms(if any), hematologic and serologic signs at each clinic visit and by electronic communication between visits. Pharmacokinetic profiles following infusion of drug will be compared with any adverse changes, and any beneficial subjective or objective responses. When the maximum tolerated dose level is reached in any cohort , another three patients will be accrued at a preceding dose level to assure tolerability in subsequent phase 2 clinical trials.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Austria
  • Salzburg, Austria, 5020
    • 3 Medicizinische Universitatsklinik Hematologie,Internistische Onkologie
  • Salzburg, Austria, 5020
    • 3. Medizinische Universitatesclinik, Haematologie, Internistische Onkologie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and Female patients >18 years with a histologically/cytologically confirmed diagnosis of locally advanced or metastatic cancer ,for whom no anti-tumor therapy of proven benefit is available at study enrollment.
• ECOG 0-2.
• Life expectancy of at least 3 months.
• Measurable or non-measurable disease according to RECIST v1.1 criteria.
• Patients should have at least one measurable lesion or disease which is non-measurable but can be clearly be evaluated for response.
• Adequate bone marrow function as evidenced by an absolute neutrophil count :1500 cell/ul.
• Hb greater than 9.5 g/dL and a platelet count greater than 100,000/ uL.
• Renal function >50ml/min with estimated creatinine clearance (eCcr) using the Cockcroft-Gault formula or serum creatinine<1.5 mg/dL.
• Adequate hepatic function as evidenced by serum total bilirubin <3.0 mg/dL, and AST and ALT less than 5 times the upper limit of normal(ULN).
• Signed informed consent.

Exclusion Criteria:

• Patients with lymphoma, hematological cancer or glioblastoma multiforme.
• Active infection, or a fever >38.5C within three days prior to the first day of study drug dosing.
• Current or past history evidence of disease (hemolytic diathesis, hemochromatosis) that could be exacerbated by administering liposomal curcumin.
• Currently on coumadin or coumadin derivatives(oral anticoagulants), or any medications classified as cytochrome p450 inhibitors or inducers.
• Last systemic therapy less than three(3) weeks before (six weeks if treatment was with BCNU or CCNU).
• Unresolved toxicities from prior systemic anti-cancer therapy except symptomatic motor or sensory neuro-toxicities NCI-CTC Grade <2.
• Clinically significant ECG aberrations according to the discretion of the investigator.
• Left ventricular ejection fraction (LVEF) <50%.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Liposomeal curcumin ascending dose phase 1b	Drug: Liposomeal curcumin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose limiting toxicity with focus on hemolysis	The primary objectives of this study are to determine in cancer patients the safety profile of increasing doses of intravenous liposomal curcumin until the maximum tolerated dose (MTD) is determined. This will be done by assessing clinical chemistry, hematology, EKGs and urine analyses, signs and physical symptoms of adverse events.	Eight(8) weeks
Determine the maximum tolerated dose of lipocurc	The primary objectives of this study are to determine in cancer patients the safety profile of increasing doses of intravenous liposomal curcumin until the maximum tolerated dose (MTD) is determined. This will be done by assessing clinical chemistry, hematology, EKGs and urine analyses, signs and physical symptoms of adverse events.	in the cohort after eight ( 8) weeks of treatment
Maximum tolerated dose	The primary objectives of this study are to determine in cancer patients the safety profile of increasing doses of intravenous liposomal curcumin until the maximum tolerated dose (MTD) is determined. This will be done by assessing clinical chemistry, hematology, EKGs and urine analyses, signs and physical symptoms of adverse events.	eight(8) weeks
Maximum tolerated dose defined by < Grade 1 hematologic toxicity,	The MTD is reached when two or more patients (out of 6) at a dose level experience DLT.	Outcome measured weekly x 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response by Recist criteria	The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of beneficial effect associated with the treatment.	Eight(8) weeks
Tumor response by resist criteria	The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of beneficial effect associated with the treatment.	8 weeks
Tumor response	The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of beneficial effect associated with the treatment.	Eight weeks
Benefit	The secondary objectives are to determine the PK profiles of increasing doses, up to the MTD of liposomal curcumin, and to record any evidence of related beneficial effect associated with the treatment.	Eight(8) weeks
Objective change in measurable tumor size by Resist criteria		once after 8 weeky treatments

Other Outcome Measures

Outcome Measure	Time Frame
Serologic changes in hepatic, renal, cardiac parameters	weekly x 8 weeks

Collaborators and Investigators

• Sponsor: SignPath Pharma, Inc.
• Investigators: Principal Investigator: Richard Greil, MD, Medicizinische Universitatsklinik Hematologie,Internistische Onkologie

Study record dates

Study Major Dates

• Study Start: March 1, 2014
• Primary Completion (Actual): November 30, 2017
• Study Completion (Actual): February 15, 2018

Study Registration Dates

• First Submitted: May 14, 2014
• First Submitted That Met QC Criteria: May 14, 2014
• First Posted (Estimate): May 15, 2014

Study Record Updates

• Last Update Posted (Actual): May 11, 2022
• Last Update Submitted That Met QC Criteria: May 5, 2022
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Antineoplastic Agents; Curcumin
• Other Study ID Numbers: Lipocurc1002/P-1-010; 0011594-24; SPP1002 (Other Identifier: SignPath Pharma,Inc); 2013-001594-24 (EudraCT Number)